Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Common Equity (2016 - 2025)

Historic Common Equity for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $192.3 million.

  • Summit Therapeutics' Common Equity fell 5609.63% to $192.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.3 million, marking a year-over-year decrease of 5609.63%. This contributed to the annual value of $388.7 million for FY2024, which is 40037.07% up from last year.
  • Summit Therapeutics' Common Equity amounted to $192.3 million in Q3 2025, which was down 5609.63% from $259.4 million recorded in Q2 2025.
  • Summit Therapeutics' Common Equity's 5-year high stood at $437.9 million during Q3 2024, with a 5-year trough of $44.2 million in Q1 2024.
  • Its 5-year average for Common Equity is $159.9 million, with a median of $119.6 million in 2023.
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 6687.94% in 2024, then surged by 67885.09% in 2025.
  • Summit Therapeutics' Common Equity (Quarter) stood at $83.3 million in 2021, then skyrocketed by 52.07% to $126.7 million in 2022, then crashed by 38.66% to $77.7 million in 2023, then soared by 400.37% to $388.7 million in 2024, then plummeted by 50.54% to $192.3 million in 2025.
  • Its last three reported values are $192.3 million in Q3 2025, $259.4 million for Q2 2025, and $344.3 million during Q1 2025.